Effective management of pneumonia caused by multidrug-resistant Gram-negative pathogens requires precise antimicrobial selection and dosing optimization. Cefepime, a fourth-generation cephalosporin, plays a critical role in this therapeutic landscape due to its broad spectrum against *Pseudomonas aeruginosa* and many extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. For clinicians managing severe hospital-acquired pneumonia, understanding cefepime pneumonia dosing is essential to balance efficacy with the risk of selecting resistant organisms or causing toxicity.
Pharmacokinetic/Pharmacodynamic Principles Guiding Cefepime Dosing
Cefepime exhibits time-dependent bactericidal activity, meaning the primary driver of efficacy is the duration that the free drug concentration remains above the minimum inhibitory concentration (MIC) of the pathogen. Targeting a minimum time above MIC (T>MIC) of approximately 40-50% of the dosing interval is generally recommended for optimal outcomes against susceptible organisms like *Pseudomonas*. This pharmacodynamic target directly informs the rationale for dividing the total daily dose into multiple administrations, ensuring sustained drug exposure throughout the day to maximize microbial kill and prevent regrowth.
Standard Adult Dosing Regimens for Pneumonia
For most adults with suspected or confirmed cefepime-sensitive pneumonia, the typical starting dose is 2 grams administered intravenously every 8 hours (three times daily). This schedule provides a T>MIC that comfortably exceeds the 40-50% target for most susceptible pathogens, including *Pseudomonas aeruginosa*. In scenarios where the pathogen is known to be highly susceptible or the infection is less severe, some clinicians may opt for a 2-gram dose every 12 hours, though this is less common for serious pneumonia.
Adjustments for Obesity and Altered Volume of Distribution
Dosing based on actual body weight can lead to subtherapeutic exposures in obese patients, as the volume of distribution for cefepime may be larger than for more hydrophilic drugs. For patients with a body weight exceeding 120 kg, or with a high body mass index (BMI), it is often prudent to dose based on an adjusted body weight or ideal body weight to avoid underdosing. Conversely, in patients with significant muscle wasting or low body weight, using total body weight may be appropriate to avoid overestimation of the required dose.
Renal Impairment and Critical Dosing Considerations
Because cefepime is primarily eliminated unchanged by the kidneys, dose adjustments are mandatory in patients with moderate to severe renal impairment. For creatinine clearance (CrCl) values between 30-50 mL/min, the standard dose is typically reduced to 1 gram every 12 hours. When CrCl falls between 10-30 mL/min, the dose is usually 1 gram every 24 hours. In patients requiring hemodialysis, a standard 2-gram post-dialysis dose is generally recommended to compensate for drug removal during the procedure.
